Media Mentions

Endpoints News featured The Ivy Brain Tumor Center’s Phase 0/2 study of niraparib, GSK’s PARP inhibitor, in newly diagnosed glioblastoma patients. This study had promising results and has led the Ivy Brain Tumor Center and GSK to collaborate on a Phase 3 study of niraparib versus temozolomide in MGMT-unmethylated glioblastoma. Read more!

Good Morning Arizona spotlighted the Ivy Brain Tumor Center at Barrow Neurological Institute in recognition of Brain Tumor Awareness Month. As part of this initiative, Cold Beer and Cheeseburgers has teamed up with the Ivy Center for their annual Dine & Donate campaign. This partnership plays a crucial role in advancing vital research efforts aimed at combating brain tumors. Learn more about how you can support this important cause.

Phoenix Magazine has recognized Jacki Garcia, Nurse Educator at the Ivy Brain Tumor Center, as a 2024 Healthcare Hero. Jacki has played a crucial role in supporting our brain tumor patients through their brain cancer journeys with profound compassion and empathy.

Precision Medicine Online's article covered the Ivy Center's groundbreaking findings at the American Association for Cancer Research's annual meeting. Dr. Sanai's Phase 0/1 trial demonstrated the efficacy of AstraZeneca's AZD1390 in treating glioblastoma. These findings offer new hope for patients with limited treatment options. Learn more!

Endpoints News highlighted Dr. Nader Sanai’s groundbreaking research with AstraZeneca's AZD1390 in glioblastoma treatment at AACR 2024. The Phase 0 study, led by Dr. Sanai, Director of the Ivy Brain Tumor Center, demonstrates the drug's efficacy in penetrating brain tissue—a pivotal advancement in glioblastoma therapy. Learn more!

Biopharma Reporter featured the Ivy Brain Tumor Center's presentation at the AACR Annual Meeting 2024, where groundbreaking advancements in glioblastoma research were highlighted. The Ivy Center unveiled promising results from their clinical trials, particularly the potential of AZD1390 as an effective radiosensitizer for treating recurrent glioblastoma.

AZBio spotlighted Dr. Nader Sanai's presentation at the American Association for Cancer Research Annual Meeting, where the Ivy Brain Tumor Center revealed promising results from a Phase 0/1b clinical trial of AZD1390 combined with radiation therapy for newly diagnosed, MGMT-unmethylated glioblastoma. These findings indicate that AZD1390, an ATM kinase inhibitor, enhances radiation therapy by preventing acute DNA damage repair. Read the full story!

The Working Mom Hour Podcast featured Dr. Charuta Furey, a neurosurgery resident at Barrow Neurological Institute and the Ivy Brain Tumor Center. From navigating tough conversations with families to balancing the demands of her career with motherhood, Dr. Furey's insights offer invaluable guidance. She dives into the significance of empathy in patient care and the importance of preparation for surgery and provides practical strategies for both medical professionals and patients alike. Listen now!

Michelle Palacino, a dedicated caregiver in the brain tumor community and an employee at the Ivy Brain Tumor Center, was recently featured on the "Rare Enough" podcast, hosted by DJ Stewart for Head for the Cure. In this episode, Michelle discusses her personal experiences and the challenges she faces, highlighting her steadfast commitment to combating brain cancer.

Featured in Women in Onc on Healio, Dr. Kelly Braun and Dr. Yoshie Umemura of the Ivy Brain Tumor Center at Barrow Neurological Institute are at the forefront of developing new treatments for aggressive brain tumors, such as glioblastoma. Their focus on translational clinical research strives to rapidly convert laboratory breakthroughs into clinical applications. They share insights on mentorship, teamwork, and the crucial balance between professional duties and personal life, providing invaluable guidance for women aspiring to leadership roles in oncology.